PREDICT Breast Cancer 5- and 10-year Survival (Bands)
PREDICT v3 (2024) is a Cambridge online tool estimating absolute benefit of adjuvant chemotherapy / endocrine / trastuzumab / bisphosphonates / chemo+olaparib (BRCA) in early breast cancer. This calc lets you record the calculated 10-year overall survival band and treatment recommendation summary. Always run the live tool at predict.nhs.uk for individualised numbers.
Score interpretation
→ Adjuvant therapies offer marginal absolute benefit. Endocrine alone often sufficient (ER+). Discuss patient preference re: chemotherapy in low-risk disease.
→ Endocrine ± targeted therapy. Chemotherapy adds modest absolute benefit — Oncotype DX / EndoPredict to refine in ER+/HER2−/N0.
→ Multi-modal adjuvant therapy adds meaningful absolute benefit. Discuss chemo + endocrine + HER2-targeted as appropriate. Consider clinical trial.
→ Aggressive multi-agent chemotherapy + targeted therapy + bisphosphonate (zoledronate per AZURE). BRCA testing for olaparib eligibility (OlympiA). Trial enrolment.
Interpretation bands for the PREDICT Breast. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Ianalumab (Anti-BAFF — Primary Sjögren's Syndrome) · Anti-BAFF Monoclonal Antibody (B-Cell Survival Factor Inhibitor)
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.